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Background: A substantial group of patients with cholestatic liver disease in infancy excrete, as the major
urinary bile acids, the glycine and taurine conjugates of 7a-hydroxy-3-oxo-4-cholenoic acid and 7a,12a-
dihydroxy-3-oxo-4-cholenoic acid. It has been proposed that some (but not all) of these have mutations in
the gene encoding D4-3-oxosteroid 5b-reductase (SRD5B1; AKR1D1, OMIM 604741).
Aims: Our aim was to identify mutations in the SRD5B1 gene in patients in whom chenodeoxycholic acid
and cholic acid were absent or present at low concentrations in plasma and urine, as these seemed strong
candidates for genetic 5b-reductase deficiency.
Patients and subjects: We studied three patients with neonatal onset cholestatic liver disease and normal
c-glutamyl transpeptidase in whom 3-oxo-D4 bile acids were the major bile acids in urine and plasma and
saturated bile acids were at low concentration or undetectable. Any base changes detected in SRD5B1
were sought in the parents and siblings and in 50 ethnically matched control subjects.
Methods: DNA was extracted from blood and the nine exons of SRD5B1 were amplified and sequenced.
Restriction enzymes were used to screen the DNA of parents, siblings, and controls.
Results: Mutations in the SRD5B1 gene were identified in all three children. Patient MS was homozygous
for a missense mutation (662 C.T) causing a Pro198Leu amino acid substitution; patient BH was
homozygous for a single base deletion (511 delT) causing a frame shift and a premature stop codon in
exon 5; and patient RM was homozygous for a missense mutation (385 C.T) causing a Leu106Phe amino
acid substitution. All had liver biopsies showing a giant cell hepatitis; in two, prominent extramedullary
haemopoiesis was noted. MS was cured by treatment with chenodeoxycholic acid and cholic acid; BH
showed initial improvement but then deteriorated and required liver transplantation; RM had advanced
liver disease when treatment was started and also progressed to liver failure.
Conclusions: Analysis of blood samples for SRD5B1 mutations can be used to diagnose genetic 5b-
reductase deficiency and distinguish these patients from those who have another cause of 3-oxo-D4 bile
aciduria, for example, severe liver damage. Patients with genetic 5b-reductase deficiency may respond
well to treatment with chenodeoxycholic acid and cholic acid if liver disease is not too advanced.
I
n 1988, Clayton et al and Setchell et al reported that, in
some infants with liver disease, the major urinary bile acids
were the glycine and taurine conjugates of 7a-hydroxy-3-
oxo-4-cholenoic acid and 7a,12a-dihydroxy-3-oxo-4-chole-
noic acid.1 2 This suggested reduced activity of the enzyme
responsible for saturating the D4 double bond during the
synthesis of bile acids from cholesterol (that is, D4-3-
oxosteroid 5b-reductase deficiency). However, it was not
clear which, if any, of these patients had defects in the gene
encoding the 5b-reductase enzyme. Some clearly had a
recognised cause of liver disease such as tyrosinaemia or
hepatitis B,1 suggesting that their ‘‘5b-reductase deficiency’’
was secondary to liver damage rather than a primary genetic
defect. However, Shneider et al described excretion of 3-oxo-
D4 bile acids as the major urinary bile acids in two unrelated
infants with features of neonatal haemochromatosis and they
suggested that 5b-reductase deficiency was the cause of
neonatal haemochromatosis.3
In 1994, Kondo et al reported the cDNA sequence for
human 5b-reductase.4 Sumazaki et al used this information to
investigate the possibility of primary 5b-reductase deficiency
in a Japanese neonate with liver failure and 3-oxo-D4 bile
aciduria.5 Using liver tissue, they sequenced the entire cDNA
for the enzyme and showed that it was normal, effectively
excluding genetic 5b-reductase deficiency. Meanwhile,
Clayton et al described a cholestatic infant in whom the
presence of large amounts of 3-oxo-D4 bile acids in plasma
and urine was associated with low concentrations of
chenodeoxycholic acid and cholic acid.6 This infant had
failed to improve on ursodeoxycholic acid therapy but liver
function returned to normal on replacement of the natural
primary bile acids, chenodeoxycholic acid and cholic acid. It
was argued that this girl probably did have a primary genetic
5b-reductase deficiency. This paper describes the identifica-
tion of a homozygous missense mutation in her 5b-reductase
gene and identification of different homozygous mutations in
the 5b-reductase genes of two other infants, both of whom
had liver disease severe enough to require transplantation.
PATIENTS AND METHODS
All studies were undertaken with permission from the
Research Ethics Committee of Great Ormond Street
Hospital/Institute of Child Health.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: AST, aspartate aminotransferase; ALT, alanine
aminotransferase; c-GT, c-glutamyl transpeptidase; ALP, alkaline
phosphatase; APTT, activated partial thromboplastin time; LSIMS, liquid
secondary ionisation mass spectrometry; ESI-MS/MS, electrospray
ionisation tandem mass spectrometry; PCR, polymerase chain reaction;
GC-MS, gas chromatography-mass spectrometry; BSEP, bile acid export
pump; FXR, farnesoid X receptor
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Patient MS
This is the Sardinian girl described previously.6 She was the
second child of healthy parents who were not knowingly con-
sanguineous. She presented at three weeks with hyperbili-
rubinaemia (316 mM, conjugated 145), raised transaminases
(aspartate aminotransferase (AST) 2279 U/l; alanine amino-
transferase (ALT) 1123 U/l), and a prolonged prothrombin
time (15.4 seconds; control 12). Cholestasis persisted and
was associated with steatorrhoea, failure to thrive, and
rickets. A liver biopsy at three months showed lobular
disarray resulting from extensive giant cell transformation
and necrotic foci with granulocyte accumulation. Hepatocytes
contained fat and bile pigment. Failure to thrive, steator-
rhoea, and fat soluble vitamin malabsorption continued
despite ursodeoxycholic acid treatment. At eight months her
bilirubin was still elevated (88 mM; conjugated 35 mM ), as
were her transaminases (AST 511 U/l, ALT 252 U/l) but
c-glutamyl transpeptidase (c-GT) was normal (36 U/l). Clotting
times were normal but vitamin E was low at 4.8 mM (normal
11.5–35) despite oral supplements. The liver still showed a
giant cell hepatitis with steatosis. Treatment with 8 mg/kg/day
of chenodeoxycholic acid and 8 mg/kg/day of cholic acid
led to normalisation of liver function within three months
and she remains well with normal liver function tests at
the age of nine years (on bile acid replacement therapy).
Patient BH
BH is the first child of healthy Pakistani parents who are first
cousins. On the first day of life he became jaundiced with
dark urine and yellow stools. Cholestatic jaundice persisted
and at the age of eight weeks he was found to have a liver
edge palpable 3 cm from the right costal margin and a spleen
tip palpable 1 cm from the left costal margin. Total bilirubin
was 160 mmol/l (conjugated 82 mmol/l); ALT 333 U/l (normal
5–45); c-GT normal; alkaline phosphatase (ALP) 842 U/l (65–
265); albumin 35 g/l; cholesterol 4.6 mM; vitamin A 97 mg/l
(200–430); 25-hydroxy-vitamin D3 15 nmol/l (15–100);
vitamin E 8.1 mmol/l (11.5–35); prothrombin time 28 seconds
(12–16); activated partial thromboplastin time (APTT)
75 seconds (29–40); and thrombin time 14.1 seconds (8–
12). Abdominal ultrasound showed normal hepatic echo-
texture and a spleen of 6.4 cm (,6.0); the gall bladder could
not be seen. A HIDA scan showed no excretion of isotope into
the gut. A liver biopsy showed preserved architecture. Portal
tracts showed bile duct proliferation but no cholangiolar bile
plugging. The parenchymal cells showed marked giant cell
transformation with intracellular bile pigment accumulation
and occasional single necrotic liver cells. The appearances
were of a giant cell hepatitis but there was also marked
extramedullary haemopoiesis. Investigations for known
causes of hepatitis of infancy were negative except for
analysis of plasma and urine bile acids.
BH was treated with chenodeoxycholic acid (8 mg/kg/day)
and cholic acid (8 mg/kg/day). Prior to starting treatment, his
bilirubin was 446 mmol/l, albumin 31 g/l, ALT 1702 U/l, c-GT
103 U/l (normal 20–155), and prothrombin time (post
parenteral vitamin K) 19 seconds. After six weeks of
treatment, values were bilirubin 117, albumin 37, ALT 184,
c-GT 243 (10–100), and prothrombin time 13 seconds. At this
point the infant had obvious pruritus and a plasma
chenodeoxycholic acid concentration of 128 mmol/l (0.2–
12.7). Chenodeoxycholic acid was stopped. Liver function
tests started to deteriorate and this continued despite
reintroduction of chenodeoxycholic acid. The infant had a
lymphocytosis and a positive polymerase chain reaction
(PCR) test (but negative IgM and immunofluorescent
antigen tests) for cytomegalovirus. Further acute deteriora-
tion (prothrombin ratio 2.1) led to referral for liver
transplantation. This was undertaken successfully and the
patient is well at the age of 2 years 10 months.
Patient RM
RM was the second child of Sri Lankan parents who are first
cousins. Their first child died at four months from
asphyxiating thoracic dystrophy plus cystic malformation of
both kidneys. RM was born at 43 weeks gestation and was
breast fed. She was treated with phototherapy from day 3 to
day 6 because of neonatal jaundice and she presented with
jaundice again at two weeks, this time with pale stools and
dark urine. Examination at four weeks revealed no hepato-
megaly or splenomegaly. Blood tests showed a total bilirubin
of 195 mmol/l (conjugated 155); AST 680 U/l; ALT 559 U/l;
ALP 818 U/l; c-GT 29 U/l (normal); lactate dehydrogenase
1496 U/l; and cholesterol 6 mM (1.2–4.6). Prothrombin time
and APTT were immeasurably prolonged but corrected almost
completely with parenteral vitamin K.
Blood and urine tests for causes of neonatal hepatitis were
negative apart from the bile acid abnormalities described
below. Ultrasound of the abdomen showed a normal sized
liver and spleen, a small gall bladder, and some irregularity in
liver density. A liver biopsy revealed a giant cell hepatitis, no
increase in bile ducts, and no signs of copper or iron
accumulation. Increased extramedullary haematopoiesis
was noted.
By the age of six weeks, liver function had deteriorated
significantly (international normalised ratio 2.0, APTT
.190 seconds, bilirubin 365 mmol/l, ALT 785). She was
treated with ursodeoxycholic acid (30 mg twice daily).
Bilirubin fell slightly, to 207 mmol/l at 10 weeks. From
10 weeks, RM was treated with chenodeoxycholic acid
(10 mg three times daily). There was no improvement in
liver function tests and the development of liver failure led to
referral for transplantation at 19 weeks. One day after
transplantation the patient developed severe cerebral oedema
with absence of all reflexes and one day later she died.
Plasma and urine bile acid analyses
Urine samples from MS and BH were analysed by liquid
secondary ionisation mass spectrometry (LSIMS), as
described previously.6 7 A urine and plasma sample from
RM were analysed by electrospray ionisation tandem mass
spectrometry (ESI-MS/MS) using a ‘‘parents of m/z 74’’ scan
for glycine conjugates and a ‘‘parents of m/z 80’’ scan for
taurine conjugates.8 Analyses of (non-sulphated) plasma and
urine bile acids by gas chromatography-mass spectrometry
(GC-MS) were undertaken using established methods.6 7 9
Analysis of the 5b-reductase gene (SRD5B1)
Initial genetic studies of 5b-reductase focused on the
characterisation of cDNA from liver biopsy samples.10
Subsequent to the determination of the genomic sequence
of SRD5B1,11 studies concentrated on genomic DNA: the nine
exons of the gene from each patient were amplified using a
single round of PCR utilising a Gene Amp PCR System 9700
machine with Bioline Taq polymerase. The temperature
program included an initial denaturing step of 94 C˚ for four
minutes followed by 28 cycles of denaturing at 94 C˚ for one
minute, annealing at 60 C˚ for one minute 30 seconds, and
extension at 72 C˚ for two minutes 15 seconds. A final
extension step of 72 C˚ for seven minutes was also employed.
Details of the primer pairs used are given in table 1. Direct
sequencing of exon amplimers was achieved using an ABI
Prism 377 automated DNA sequencer with ABI Prism Dye
Terminator Cycle Sequencing reactions. Once putative muta-
tions were found, parents and control populations were
screened for these mutations using restriction enzyme
digests. BanI was used to screen the exon 4 amplimer for
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the mutation found in BH, while DdeI was used to screen the
exon 3 amplimer for the mutation found in RM. FokI was
used to screen a novel amplimer (see table 1) for the
mutation found in MS.
RESULTS
Plasma and urine bile acid analyses
Analysis of urine by LSIMS or ESI-MS/MS showed that, in all
three patients, the largest bile acid peaks were consistent
with a monohydroxy-oxo-cholenoic acid present as the
glycine conjugate (m/z 444) and the taurine conjugate (m/z
494) and a dihydroxy-oxo-cholenoic acid present as the
glycine conjugate (m/z 460) and the taurine conjugate (m/z
510) (fig 1). Peaks attributable to the glycine and taurine
conjugates of chenodeoxycholic acid and cholic acid (m/z
448, 464, 498, and 514) were very small or undetectable
above background. The sample from BH showed an
additional prominent peak of mass/charge ratio 552, con-
sistent with a taurine conjugated dihydroxy-oxo-cholestenoic
acid (fig 1). Analysis of plasma and urine samples from MS
and BH by GC-MS following treatment with cholylglycine
hydrolase confirmed that the major bile acids were 7a-
hydroxy-3-oxo-4-cholenoic acid and 7a,12a-dihydroxy-3-
oxo-4-cholenoic acid (table 2). Chenodeoxycholic acid was
undetectable in both plasma samples; cholic acid was absent
from the plasma of MS and present in a trace amount in the
plasma of BH. Analysis of plasma from MR by ESI-MS/MS
indicated that mono- and di-hydroxy-oxocholenoic acids
were the major bile acids; chenodeoxycholic acid and cholic
acid concentrations were normal/low. (The true concentra-
tions may have been lower than those shown in table 2; there
is the potential for isomeric compounds such as allo bile acids
to interfere with analysis of chenodeoxycholic acid and cholic
acid by ESI-MS/MS.)
Analysis of the 5b-reductase gene (SRD5B1)
A point mutation or single base deletion was found in all
three patients. The results of the sequencing and restriction
enzyme digests are summarised in table 3. All three patients
were homozygous for their mutation and all parents were
heterozygotes, as was an unaffected sibling of BH. The point
mutation found in MS (662 C.T) was not found in a control
population of 100 chromosomes; 38 of these were from the
Sardinian population and the remaining 62 were unspecified
Caucasian samples. The mutations found in patients BH (511
delT) and RM (385 C.T) and were not found in 100
chromosomes from individuals from the Indian subconti-
nent.
DISCUSSION
Analysis of bile acids and alcohols in plasma and urine has
become an essential part of the investigation of infants with
cholestatic jaundice. Several characteristic cholanoid profiles
have led to the discovery of mutations in genes encoding
enzymes in the bile acid synthesis pathways. These include
inborn errors affecting 3b-hydroxy-D5-C27-steroid dehydro-
genase/isomerase,12 13 oxysterol 7a-hydroxylase,14 sterol 27-
hydroxylase,15 16 and a-methyl-acyl-CoA racemase.17 18
Cholanoid analyses have also helped to define gene defects
that affect peroxisome biogenesis7 9 or peroxisomal b-oxida-
tion enzymes;19–21 in most of these disorders neurological
symptoms dominate the clinical picture.22 23
To date, it has proved difficult to establish that infants with
cholestatic liver disease and a cholanoid profile characterised
by excretion of 3-oxo-D4 bile acids have a genetic deficiency
of D4-3-oxosteroid 5b-reductase. In some infants, the liver
biopsy showed absence of immunoreactive 5b-reductase
protein or a truncated protein and this was taken as evidence
of a genetic deficiency.3 However, the possibility of a labile
mRNA or protein could not be excluded.
Determination of the human 5b-reductase cDNA sequence4
allowed Sumazaki et al to show that, in at least one infant
with liver failure, the 5b-reductase mRNA had a normal
sequence.5 This confirmed the suspicion that some children
who excrete 3-oxo-D4 bile acids as the major urinary bile
acids do not have genetic 5b-reductase deficiency.
Patient MS had cholanoid profiles that showed almost
complete absence of chenodeoxycholic acid and cholic acid.
Her liver disease resolved completely on treatment with
chenodeoxycholic acid plus cholic acid having failed to
respond to ursodeoxycholic acid. This suggested strongly
that she had mutations in the 5b-reductase gene. Sequencing
of her genomic DNA showed that she was homozygous for a
single base substitution 662 C.T. The base substitution
abolishes the 5 base recognition sequence for the restriction
enzyme FokI. Restriction fragment length analyses showed
that the patient’s parents were heterozygous for the mutation
and that it could not be detected in 100 ethnically matched
genomic DNA samples, excluding the possibility that it was a
Table 1 Primer pairs for each exon of the 5b-reductase
gene and the primer used to generate an amplimer
suitable for restriction enzyme digest in patient MS
Exon 1 Forward ggtgtgttaatctcccttccc
Backward aagaaacaaacaagcaagcaaag
Exon 2 Forward tttctcttttccccaaaccc
Backward cacacacacacacacggaag
Exon 3 Forward gggctgccttatcgtaaaaa
Backward acctttgggcatctgaactc
Exon 4 Forward gctcacaattatgaagactggg
Backward tgaaagtaaagggtgcatctctc
Exon 5 Forward ggcttgtttgttgacctgtg
Backward tcatgagccttcctgactcc
Exon 6 Forward ttgtgctctgctctccaatg
Backward accaaaaggcattccaatca
Exon 7 Forward gtgactgggtgaatgggaag
Backward ttcacatctccaaaagcaattc
Exon 8 Forward tgatcccaagcttgaccttc
Backward gactacgttgctagctagc
Exon 9 Forward tctgtgggggaattgttttg
Backward tgagtcaaagtcatttacactgcac
MS RE product Forward tgttcttgaatccattttaaggaagc
Backward cctttggggaccagtaggaatc
0
100
%
440 450 460 470 480 490 500
m/z
510 520 530 540 550 560 570
444
460
494
510
552
Figure 1 Negative ion liquid secondary ionisation mass spectrometry
(LSIMS) analysis of a urine sample from patient BH. Identities of peaks
(confirmed by gas chromatography-mass spectrometry): m/z 444 and
460, glycine conjugates of 7a-hydroxy-3-oxo-4-cholenoic acid and
7a,12a-dihydroxy-3-oxo-4-cholenoic acid; m/z 494, 510, and 552,
taurine conjugates of 7a-hydroxy-3-oxo-4-cholenoic acid, 7a,12a-
dihydroxy-3-oxo-4-cholenoic acid, and 7a,12a-dihydroxy-3-oxo-4-
cholestenoic acid.
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common polymorphism in Caucasians. The 662 C.T muta-
tion is a missense mutation that leads to the amino acid
substitution Pro198Leu in the 5b-reductase protein.
Comparison of the predicted secondary structure of 5b-
reductase with two other NADPH binding proteins, glu-
tathione reductase and NADPH-cytochrome P-450 reductase,
suggests that proline 198 is in the NADPH binding domain of
the 5b-reductase protein.4 Substitution of a leucine residue
for the proline residue can be predicted to alter the secondary
structure of this domain. Thus even if the protein is
translated normally and escapes quality control processes,
the mutant enzyme is unlikely to bind NADPH normally and
is therefore likely to be catalytically inactive.
Patient BH, like MS, had cholanoid profiles that showed
almost undetectable amounts of chenodeoxycholic acid and
cholic acid. He also showed an initial response to treatment
with chenodeoxycholic acid and cholic acid, although a
subsequent deterioration, perhaps due to cytomegalovirus
infection, meant that he needed a liver transplant. Again, the
clinical and biochemical features strongly suggested muta-
tions in the 5b-reductase gene. Analysis of genomic DNA
showed that he was homozygous for a mutation, 511delT,
that produces a premature stop codon in exon 5. This
mutation can be predicted to produce a truncated, catalyti-
cally inactive protein. Analysis of genomic DNA from BH’s
parents and his unaffected sibling showed that they were
heterozygous for the 511delT mutation.
Patient RM also had a urinary cholanoid profile (showing
mz 444..448, 460..464, 494..498, and 510..514) that
suggested a major block in the synthesis of chenodeoxycholic
acid and cholic acid, compatible with mutations in the 5b-
reductase gene. Analysis of her plasma by ESI-MS suggested
that some synthesis of chenodeoxycholic acid and cholic acid
may be occurring although the concentrations were still low
for an infant with cholestatic jaundice. Treatment with bile
acids was only started when her liver disease was quite
advanced. She showed slight improvement in her cholestasis
with ursodeoxycholic acid but no further improvement with
chenodeoxycholic acid. Nevertheless, she too seemed a good
candidate for genetic 5b-reductase deficiency; we knew from
our experience with BH that this disorder could progress to
liver failure in infancy. Analysis of genomic DNA showed that
she was homozygous for a missense mutation (385 C.T).
The Leu106Phe substitution occurs within the alpha-3 helix
of the 5b-reductase enzyme. Leucine 106 is conserved within
41 of the 42 members of the aldo keto-reductase super family
(98%) according to the alignments published by Jez and
colleagues.24 The missense mutation in RM might produce
5b-reductase enzyme with a little residual activity. This
would explain why the plasma concentrations of cheno-
deoxycholic acid and cholic acid were apparently higher than
in the two other patients.
Detection of SRD5B1mutations in these three patients
allows us to define the effects of genetic 5b-reductase
deficiency. All three patients had cholestatic liver disease of
neonatal onset; liver function tests showed a normal c-GT at
a time when transaminases were considerably elevated. This
phenomenon, as well as evidence of malabsorption of fat and
fat soluble vitamins, is seen in other defects of bile acid
synthesis (for example, 3b-hydroxysteroid-D5-C27-steroid
dehydrogenase deficiency) as well as in defects of bile acid
secretion (for example, progressive familial intrahepatic
cholestasis type II due to mutations in the gene encoding
the bile acid export pump (BSEP)). The reason for the low
c-GT in these patients is not certain. It is known that c-GT is
normally located on microvilli at the canalicular surface of
hepatocytes and bile duct epithelial cells. It is probably only
released from the microvilli when bile acids are secreted into
the canaliculi and exert a detergent effect on the membranes
lining the biliary system. Thus if bile acids are not entering
the canaliculi there is reduced production of the soluble form
of c-GT that normally accumulates in the circulation in
response to damage to bile ducts and hepatocytes.
The bile acid profiles in all three patients with SRD5B1
mutations showed amounts of chenodeoxycholic acid and
cholic acid that were very low for an infant with cholestasis;
this is consistent with the notion that D4-3-oxosteroid 5b-
reductase is required for all biosynthetic pathways for the
major primary bile acids. Failure to synthesise chenodeoxy-
cholic acid and cholic acid may lead to low hepatocyte
Table 2 Plasma concentrations of chenodeoxycholic acid and cholic acid and their 3-oxo-D4 analogues in the plasma of
children with mutations in the SRD5B1 gene causing D4-3-oxosteroid 5b-reductase deficiency
Bile acid
Plasma concentration (mmol/l)
Patient MS*
(age 8 months)
Patient BH*
(age 2.5 months)
Patient RM
(age 4 weeks) Normal infants
Infants with
cholestasis
Chenodeoxycholic acid ,0.05 ,0.05 0.9 0.2–12.7 13.4–181
Cholic acid ,0.05 0.26 4.0 0.4–6.7 4.7–403
7a-hydroxy-3-oxo-4-cholenoic acid 1.9 6.7 2.1 ,0.05 0–6.5
7a, 12a-dihydroxy-3-oxo-4-cholenoic
acid
2.1 7.6 2.9 ,0.05 0–4.4
*Measured by gas chromatography-mass spectrometry following enzymatic deconjugation.
Measured by electrospray ionisation tandem mass spectrometry—may overestimate concentrations of chenodeoxycholic acid and cholic acid because of
interference from isomers.
Table 3 Summary of the mutations found on DNA sequencing of the 5b-reductase gene
and subsequent restriction digest of parental/sibling DNA
Patient Sequencing Restriction enzyme digest
MS 662 C.T missense mutation causing a Pro198Leu
amino acid substitution
Parents heterozygous for the 662 C.T missense
mutation
BH 511T deletion causing frame shift and a premature
stop codon in exon 5
Parents and unaffected sibling heterozygous for the
511T deletion
RM 385 C.T missense mutation causing a Leu106Phe
amino acid substitution
Parents heterozygous for the 385 C.T missense
mutation
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concentrations of these bile acids with consequent failure to
activate the farnesoid X receptor (FXR) and hence switch on
the bile acid export pump (BSEP) and the canalicular
conjugated bilirubin transporter (MRP2).25 Failure to activate
MRP2 may contribute to the jaundice in these patients and
also to poor excretion of HIDA.
There are some significant differences between the
biochemical findings in these three patients and other
putative cases of 5b-reductase deficiency. Thus the cases
reported by Setchell and colleagues2 and Kimura and
colleagues26 27 had elevated plasma concentrations of cheno-
deoxycholic acid and a high ratio of chenodeoxycholic acid to
cholic acid. Other cases reported by Kimura et al had
increased concentrations of total plasma bile acids (method
of assay and chenodeoxycholic acid/cholic acid ratio not
specified).28 Our own experience is that many infants with
severe liver disease (and some infants with milder disease)
show this pattern of high plasma chenodeoxycholic acid,
high cheno/cholic ratio, and moderate 3-oxoD4 bile acid-
uria—it is much commoner than the profiles described above
for patients with proven SRD5B1mutations. There are four
possible explanations for a cholanoid profile characterised by
increased excretion of 3-oxo-D4 bile acids in urine and a high
plasma chenodeoxycholic acid concentration.
N These patients have SRD5B1 mutations that leave some
residual 5b-reductase activity. Some chenodeoxycholic
acid is synthesised and inhibition of BSEP by 3-oxo-D4
bile acids29 causes reflux of bile acids into the plasma
leading to elevated plasma concentrations.
N These patients do not have a genetic defect in the SRD5B1
gene but rather secondary changes in the liver lead to
inactivation of the 5b-reductase enzyme. The 5b-reductase
protein may be unstable; certainly early attempts at
purification proved problematical.30 It may be prone to
chemical attack. Zhu et al showed that it can form adducts
with acetaldehyde in vivo.31
N There are no mutations in the SRD5B1 gene but the
amount of mRNA in liver cells is reduced. mRNA may be
unstable. Kondo et al showed that the 39 untranslated
region of the 5b-reductase mRNA contained multiple AU
rich elements.4 Such AUREs are associated with rapidly
degrading mRNAs such as those encoding cytokines and
lymphokines.32 It is also possible that expression of
SRD5B1 is regulated by transcription factors as is the case
with other key enzymes in oxysterol metabolism and bile
acid synthesis (see below).
N These patients have persistence of, or reversion to, the fetal
pattern of bile acid metabolism. The major pathway of bile
acid synthesis in the fetus probably starts with the
production of 27-hydroxycholesterol and produces mainly
chenodeoxycholic acid.14 This is the predominant bile acid
in the fetus; however, significant amounts of 7a-hydroxy-
3-oxo-4-cholenoic acid are also produced.33 BSEP is
probably inactive in fetal life34 and it is therefore likely
that a substantial proportion of the chenodeoxycholic acid
(and 7a-hydroxy-3-oxo-4-cholenoic acid) synthesised in
the hepatocyte enter the blood stream. Increased cholic
acid synthesis and activation of the BSEP normally occur
at the time of birth; if this activation does not occur and
the fetal pattern of bile acid metabolism persists, one
would predict high plasma chenodeoxycholic acid, high
cheno/cholic ratio, and 7a-hydroxy-3-oxo-4-cholenoic acid
in plasma. It is becoming clear that regulation of bile
acid synthesis and secretion is controlled by nuclear
receptors such as FXR, and to a lesser extent by the liver
X receptors and the pregnane X receptor/steroid and
xenobiotic receptor.25 35 Recent studies suggest that full
activation of the BSEP might require the natural analogue
of guggulsterone as well as chenodeoxycholic acid (a
known agonist at the FXR receptor).36 It is possible
therefore that persistence of a fetal pattern of bile acid
synthesis and secretion is caused by failure of activation of
transcription factors (including FXR) by the natural
analogue of guggulsterone.
Further work is required to establish whether patients
with 3-oxo-D4 bile aciduria and elevated plasma cheno-
deoxycholic acid concentrations have mutations in the
SRD5B1 gene or whether they have other gene defects or
non-genetic liver diseases that lead to secondary reduction
in 5b-reductase enzyme activity. This is of more than
academic interest. Treatment with chenodeoxycholic acid
and cholic acid was extremely effective in one of our
patients with SRD5B1 mutations (the only one for whom
treatment was started when bilirubin was ,200 mM, ALT
was ,600 U/l, and the post vitamin K prothrombin time
was normal). In patients with high plasma cheno-
deoxycholic acid concentrations, the combination of urso-
deoxycholic acid and cholic acid appeared to be more
effective.2 In the future, nuclear receptor agonists may have
a role in carefully defined patients. Based on our current
knowledge of 5b-reductase mutations, a suggested algorithm
for diagnosis of genetic 5b-reductase deficiency is shown
in fig 2.
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Plasma bile acid analysis by GC-MS
Major bile acids are 7α-OH-3-oxo-4-cholenoic
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Look for other causes of
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Sequence SRD5B1
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Primary genetic 5β-reductase deficiency
Y N
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Figure 2 Suggested algorithm for distinguishing between primary
genetic 5b-reductase deficiency and other cause of 3-oxo-D4 bile
aciduria. ESI-MS/MS, electrospray ionisation tandem mass
spectrometry; GC-MS, gas chromatography-mass spectrometry; FAB-
MS, fast atom bombardment-mass spectrometry.
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